These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 25353163)
1. Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2. Xiao Q; Tan Y; Guo Y; Yang H; Mao F; Xie R; Wang B; Lei T; Guo D PLoS One; 2014; 9(10):e111419. PubMed ID: 25353163 [TBL] [Abstract][Full Text] [Related]
2. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling. Xiao Q; Dong M; Cheng F; Mao F; Zong W; Wu K; Wang H; Xie R; Wang B; Lei T; Guo D Int J Oncol; 2018 Sep; 53(3):1069-1082. PubMed ID: 30015847 [TBL] [Abstract][Full Text] [Related]
3. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation. Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613 [TBL] [Abstract][Full Text] [Related]
4. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Goldoni S; Iozzo RA; Kay P; Campbell S; McQuillan A; Agnew C; Zhu JX; Keene DR; Reed CC; Iozzo RV Oncogene; 2007 Jan; 26(3):368-81. PubMed ID: 16847455 [TBL] [Abstract][Full Text] [Related]
5. Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1. Yi W; Holmlund C; Nilsson J; Inui S; Lei T; Itami S; Henriksson R; Hedman H Exp Cell Res; 2011 Feb; 317(4):504-12. PubMed ID: 21087604 [TBL] [Abstract][Full Text] [Related]
6. Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro. Wang B; Han L; Chen R; Cai M; Han F; Lei T; Guo D Cancer Biol Ther; 2009 Jun; 8(11):1018-23. PubMed ID: 19421009 [TBL] [Abstract][Full Text] [Related]
7. LRIG3 modulates proliferation, apoptosis and invasion of glioblastoma cells as a potent tumor suppressor. Guo D; Yang H; Guo Y; Xiao Q; Mao F; Tan Y; Wan X; Wang B; Lei T J Neurol Sci; 2015 Mar; 350(1-2):61-8. PubMed ID: 25708990 [TBL] [Abstract][Full Text] [Related]
8. LRIG1 enhances the radiosensitivity of radioresistant human glioblastoma U251 cells via attenuation of the EGFR/Akt signaling pathway. Yang JA; Liu BH; Shao LM; Guo ZT; Yang Q; Wu LQ; Ji BW; Zhu XN; Zhang SQ; Li CJ; Chen QX Int J Clin Exp Pathol; 2015; 8(4):3580-90. PubMed ID: 26097540 [TBL] [Abstract][Full Text] [Related]
9. LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Hedman H; Lindström AK; Tot T; Stendahl U; Henriksson R; Hellberg D Acta Oncol; 2010 Aug; 49(6):812-5. PubMed ID: 20553099 [TBL] [Abstract][Full Text] [Related]
11. Lrig2-deficient mice are protected against PDGFB-induced glioma. Rondahl V; Holmlund C; Karlsson T; Wang B; Faraz M; Henriksson R; Hedman H PLoS One; 2013; 8(9):e73635. PubMed ID: 24023893 [TBL] [Abstract][Full Text] [Related]
12. In vivo analysis of Lrig genes reveals redundant and independent functions in the inner ear. Del Rio T; Nishitani AM; Yu WM; Goodrich LV PLoS Genet; 2013; 9(9):e1003824. PubMed ID: 24086156 [TBL] [Abstract][Full Text] [Related]
13. Characterization and tissue-specific expression of human LRIG2. Holmlund C; Nilsson J; Guo D; Starefeldt A; Golovleva I; Henriksson R; Hedman H Gene; 2004 May; 332():35-43. PubMed ID: 15145052 [TBL] [Abstract][Full Text] [Related]
14. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2. Qi XC; Xie DJ; Yan QF; Wang YR; Zhu YX; Qian C; Yang SX Biochem Biophys Res Commun; 2013 Aug; 437(4):565-72. PubMed ID: 23850692 [TBL] [Abstract][Full Text] [Related]
15. A role for LRIG1 in the regulation of malignant glioma aggressiveness. Mao F; Wang B; Xiao Q; Xi G; Sun W; Zhang H; Ye F; Wan F; Guo D; Lei T; Chen X Int J Oncol; 2013 Mar; 42(3):1081-7. PubMed ID: 23337938 [TBL] [Abstract][Full Text] [Related]
16. Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Holmlund C; Haapasalo H; Yi W; Raheem O; Brännström T; Bragge H; Henriksson R; Hedman H Neuropathology; 2009 Jun; 29(3):242-7. PubMed ID: 18992012 [TBL] [Abstract][Full Text] [Related]
17. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling. Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476 [TBL] [Abstract][Full Text] [Related]
18. LRIG and cancer prognosis. Lindquist D; Kvarnbrink S; Henriksson R; Hedman H Acta Oncol; 2014 Sep; 53(9):1135-42. PubMed ID: 25180912 [TBL] [Abstract][Full Text] [Related]
19. Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line. Guo D; Han L; Shu K; Chen J; Lei T J Huazhong Univ Sci Technolog Med Sci; 2007 Feb; 27(1):91-4. PubMed ID: 17393120 [TBL] [Abstract][Full Text] [Related]